Matthews, Gail V.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science

interferon and immune responsesSARS-CoV-2 and COVID-19 Research

Cited by 2,662

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science

interferon and immune responsesSARS-CoV-2 and COVID-19 Research

Cited by 2,229

Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review.

Jin, F., Matthews, G. V., & Grulich, A. E. (2017) · Sexual Health

Hepatitis C virus researchHIV, Drug Use, Sexual Risk

Cited by 74

Invasive amebiasis in men who have sex with men, Australia.

Stark, D., van Hal, S. J., Matthews, G., Harkness, J., & Marriott, D. (2008) · Emerging infectious diseases

Amoebic Infections and TreatmentsLegionella and Acanthamoeba research

Cited by 64

Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM.

Lockart, I., Matthews, G. V., & Danta, M. (2019) · Current Opinion in Infectious Diseases

Hepatitis C virus researchHIV, Drug Use, Sexual Risk

Cited by 37

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

Matthews, G., Jacoby, S., Borok, M., Eriobu, N., Kaplan, R., Kumarasamy, N., Bennet, J. A., Avihingsanon, A., Chetchotisakd, P., Wagner Cardoso, S., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 31